Health Catalyst (NASDAQ:HCAT) Price Target Cut to $5.00 by Analysts at KeyCorp

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by KeyCorp from $7.00 to $5.00 in a research note issued on Wednesday, MarketBeat Ratings reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price target suggests a potential upside of 30.21% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada decreased their price target on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Thursday, February 27th. Evercore ISI cut shares of Health Catalyst from an “outperform” rating to an “inline” rating in a report on Wednesday, April 9th. Canaccord Genuity Group cut their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Stephens decreased their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Finally, Piper Sandler cut their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.36.

Health Catalyst Stock Performance

HCAT opened at $3.84 on Wednesday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $269.61 million, a PE ratio of -2.84 and a beta of 1.43. The business has a fifty day simple moving average of $4.50 and a 200-day simple moving average of $6.40. Health Catalyst has a fifty-two week low of $3.56 and a fifty-two week high of $9.24.

Insider Transactions at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 16,902 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at $977,450. This trade represents a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,588 shares of company stock valued at $225,906. 2.50% of the stock is owned by insiders.

Institutional Trading of Health Catalyst

Several large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new position in shares of Health Catalyst during the 4th quarter valued at $29,000. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after buying an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC bought a new position in Health Catalyst during the fourth quarter valued at about $63,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Health Catalyst in the fourth quarter worth about $77,000. Finally, Martin Worley Group bought a new stake in shares of Health Catalyst during the 4th quarter worth about $78,000. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.